Results 1 to 10 of about 178,876 (120)
Cross-protective antibodies against common endemic respiratory viruses
Nature Communications, 2023 Respiratory syncytial virus (RSV), human metapneumovirus (HMPV), and human parainfluenza virus types one (HPIV1) and three (HPIV3) can cause severe disease and death in immunocompromised patients, the elderly, and those with underlying lung disease.
Madelyn Cabán +6 more
doaj +1 more source
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
npj Vaccines, 2021 We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone. We measured
Kelly E. Seaton +29 more
doaj +1 more source
Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer
Scientific Reports, 2022 Prostate cancer is one of the few malignancies that includes vaccination as a treatment modality. Elements of an effective cancer vaccine should include the ability to elicit a Type I T-cell response and target multiple antigenic proteins expressed early
Denise L. Cecil +9 more
doaj +1 more source
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
BMC Infectious Diseases, 2022 Background Despite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still urgently needed. Several antiviral drugs have shown to be effective in reducing progression of COVID-19 disease. Methods In the present
Laura Matrajt +4 more
doaj +1 more source
npj Breast Cancer, 2021 B cell responses to tumor antigens occur early in breast tumors and may identify immunogenic drivers of tumorigenesis. Sixty-two candidate antigens were identified prior to palpable tumor development in TgMMTV-neu and C3(1)Tag transgenic mouse mammary ...
Sasha E. Stanton +9 more
doaj +1 more source
Nature Communications, 2021 Most COVID-19 vaccines require two doses but a single dose provides partial protection, so it is unclear how best to prioritize vaccine distribution in the context of limited supply.
Laura Matrajt +6 more
doaj +1 more source
Scientific Reports, 2021 Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after ...
David A. Swan +10 more
doaj +1 more source
T Cell Subsets in the Germinal Center: Lessons from the Macaque Model
Frontiers in Immunology, 2018 Germinal centers (GCs) are organized lymphoid tissue microstructures where B cells proliferate and differentiate into memory B cells and plasma cells. A few distinctive subsets of highly specialized T cells gain access to the GCs by expressing the B cell
Monica Vaccari, Genoveffa Franchini
doaj +1 more source
Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43
Viruses, 2021 The human Betacoronavirus OC43 is a common cause of respiratory viral infections in adults and children. Lung infections with OC43 are associated with mortality, especially in hematopoietic stem cell transplant recipients.
Jim Boonyaratanakornkit +7 more
doaj +1 more source
In vivo dynamics of AAV-mediated gene delivery to sensory neurons of the trigeminal ganglia
Scientific Reports, 2017 The ability to genetically manipulate trigeminal ganglion (TG) neurons would be useful in the study of the craniofacial nervous system and latent alphaherpesvirus infections.
Chung H. Dang +7 more
doaj +1 more source